Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 12, 2026
CoreWeave Delivers 112% Revenue Growth, Stock Jumps +12-15% After Hours

CoreWeave Delivers 112% Revenue Growth, Stock Jumps +12-15% After Hours

Key Takeaways

  • Revenue surged 112% year-over-year to $2.58 billion, surpassing the consensus estimate of $2.56 billion and marking the fifth consecutive revenue beat since the company's IPO.
  • Adjusted loss per share of $1.03 came in narrower than the analyst consensus of a $1.20 loss, while GAAP (Generally Accepted Accounting Principles) net loss widened to $626 million from $290 million a year ago.
  • Revenue backlog reached $104 billion, up 246% year-over-year, with an additional $25 billion in net new customer commitments signed in early Q3 not yet reflected in that figure.
  • Full-year guidance was raised: revenue now expected at $12.4–$13.2 billion and adjusted operating income at $960 million–$1.15 billion, both above prior ranges.
  • Capital expenditure guidance increased to $35–$39 billion for 2026, reflecting accelerated infrastructure deployment and higher component costs.
  • Stock surged approximately 12–15% in after-hours trading, reversing a slide of more than 30% since the prior earnings report in May.

Putting CoreWeave's Results in Context

CoreWeave's second-quarter results arrived at a pivotal moment for the AI infrastructure sector. The company, which rents GPU (Graphics Processing Unit) computing power to AI developers and enterprises, has been one of the most closely watched names in the neocloud space since its March 2025 IPO. Heading into this report, investor sentiment had soured—shares had fallen more than 30% from the stock's May post-earnings levels amid concerns about mounting debt, rising interest expenses, and whether CoreWeave could convert its enormous backlog into profitable revenue. As one of the few publicly traded pure-play AI infrastructure providers, CoreWeave's quarterly update also serves as a temperature check on broader AI capital spending trends across the technology industry. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The Quarter in Detail

CoreWeave reported second-quarter revenue of $2.58 billion for the period ended June 30, 2026, representing 112% growth from $1.21 billion in the same quarter last year. The figure landed at the high end of management's $2.45–$2.60 billion guidance range and modestly above the Wall Street consensus of $2.56 billion.

On the bottom line, the company posted a GAAP net loss of $626 million, or $1.14 per share, compared with a net loss of $290 million, or $0.60 per share, in the prior-year period. The wider loss was driven primarily by interest expense, which more than doubled to $640 million from $267 million a year earlier as the company continued to finance its data center buildout through debt. On an adjusted basis, which excludes non-recurring items, CoreWeave reported a loss of $1.03 per share, beating analyst expectations of a $1.20 loss.

Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) reached $1.51 billion, producing a margin of 59%, while adjusted operating income came in at $128 million—well above the $66 million consensus and within management's guided range of $30–$90 million.

Operationally, CoreWeave added nearly 500 megawatts (MW) of active power during the quarter, bringing total active capacity to 1.5 gigawatts (GW). Contracted power rose to approximately 3.7 GW at quarter-end and has since climbed to 4.2 GW. Capital expenditures totaled $9.4 billion for the quarter, slightly above prior guidance, as the company accelerated customer deliveries. CoreWeave also raised approximately $18 billion through a combination of debt, convertible securities, and equity during the quarter, and ended June with more than $6.9 billion in cash, restricted cash, and marketable securities.

Market Reaction

CoreWeave shares jumped approximately 12% to 15% in after-hours trading following the earnings release, recovering a meaningful portion of the steep declines suffered since the company's Q1 report in May. The stock had closed the regular session at $90.32, up 2.4% on the day, and rose as high as $103.53 in extended trading. The rally reflected relief across multiple fronts: revenue exceeded expectations, adjusted losses narrowed more than forecast, the backlog crossed the symbolic $100 billion threshold, and full-year guidance was raised rather than merely maintained. Prior to the release, options markets had priced in roughly 15% two-way volatility, and the stock had historically sold off after each of its previous quarterly reports, making the positive reaction a notable shift in market sentiment.

Forward Outlook and Risks to Watch

CoreWeave enters the second half of 2026 with considerable momentum. The company guided third-quarter revenue to $3.4–$3.6 billion, implying approximately 158% year-over-year growth at the midpoint and exceeding the $3.43 billion consensus. For the full year, management now projects revenue of $12.4–$13.2 billion and adjusted operating income of $960 million–$1.15 billion, both raised from prior guidance ranges.

Several developments merit attention in the months ahead. First, CoreWeave expects to exit 2026 with more than 1.85 GW of active power and annualized revenue run rate of $18–$19 billion, setting the stage for continued triple-digit growth. Second, the company's push into managed inference services has gained early traction, with annual recurring revenue (ARR) for the managed inference platform rising from $1 million to over $100 million in a matter of months—management targets at least $250 million in managed inference ARR by year-end. Third, CoreWeave announced its first CoreWeave Omni agreement during the quarter, with scaling expected to begin in 2027.

Risks remain material. Total balance-sheet debt reached $35 billion at quarter-end, and interest expense will continue to weigh on GAAP profitability. The newly raised capital expenditure guidance of $35–$39 billion for 2026 underscores the capital-intensive nature of CoreWeave's growth model. Additionally, competitive dynamics are evolving: SpaceX has begun selling excess compute capacity, and Meta Platforms has signaled interest in potentially entering the cloud rental market. CEO Michael Intrator addressed these concerns on the earnings call, noting that pricing and margins for next-generation Blackwell and Vera Rubin systems are reaching new highs, while earlier-generation GPU pricing remains at or above historical levels.

The $104 billion backlog—which does not yet include the $25 billion in commitments already secured in early Q3—provides substantial revenue visibility, but the pace at which CoreWeave converts that backlog into cash flow will be the defining metric for investors over the next several quarters.

Enhancing My Research Process

One tool I rely on when scanning for comparable names in the AI infrastructure space is Tickeron's AI Screener. It lets me filter thousands of stocks and ETFs using technical patterns, fundamentals, volatility, and AI-driven signals, which helps surface ideas more efficiently than manual checks alone. This approach keeps my analysis grounded in data without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRWV

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CRWV's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CRWV turned positive on July 31, 2026. Looking at past instances where CRWV's MACD turned positive, the stock continued to rise in of 12 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRWV's RSI Oscillator exited the oversold zone, of 4 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on CRWV as a result. In of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where CRWV advanced for three days, in of 79 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRWV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRWV broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRWV entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.804) is normal, around the industry mean (24.022). P/E Ratio (0.000) is within average values for comparable stocks, (72.205). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.917). CRWV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (6.203) is also within normal values, averaging (132.417).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRWV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Block Inc (NYSE:XYZ), Twilio (NYSE:TWLO), NetApp (NASDAQ:NTAP), MongoDB (NASDAQ:MDB), Zscaler (NASDAQ:ZS), Okta (NASDAQ:OKTA).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.48B. The market cap for tickers in the group ranges from 48.8K to 3.74T. MSFT holds the highest valuation in this group at 3.74T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 0%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 27%. CSAI experienced the highest price growth at 45%, while GYGY experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -21%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 73
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
CRWV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ComputerCommunications

Profile
Details
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.